NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Observational Study of Vismodegib (Erivedge) in Patients Treated in Argentina

CompletedN/A

Sponsor: Hoffmann-La Roche

Conditions: Basal Cell Carcinoma

This observational, noninterventional study is designed to further characterize the effectiveness and safety profile of vismodegib (Erivedge) in Argentine patients. Only patients with locally advanced basal cell carcinoma (laBCC) or metastatic basal cell carcinoma (mBCC) will be considered in the effectiveness analysis. Study duration is estimated to be approximately 12 months.

Eligibility overview

Sex: ALL

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Argetine patients prescribed vismodegib according to standard of care and in line with Summary of Product Characteristics (SPC) and local labeling
* Diagnosis of laBCC or mBCC for the effectiveness analysis

Exclusion Criteria:

* None specified